For the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of the following gram-positive microorganisms in adults 18 years of age and older: Staphylococcus aureus (including methicillin-resistant [MRSA]), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus Group (including Streptococcus
anginosus, Streptococcus intermedius, and Streptococcus constellatus).